Latest Asx Continuous Disclosure News

Felix Gold Limited has been found in breach of ASX continuous disclosure rules after delaying the announcement of a U.S. federal site visit to its Alaska antimony project, prompting an internal review of its disclosure policies.

Felix Gold Limited confirmed the materiality of a senior US federal officials' visit to its Treasure Creek Antimony Project, explaining the delayed disclosure was due to legal restrictions imposed by US authorities. The company affirmed compliance with ASX continuous disclosure rules following the announcement.

GoldArc Resources has responded to ASX inquiries about recent unusual trading activity, attributing it to early-stage mining discussions and anticipation of assay results from its Leonora South Gold Project.

Altitude Minerals has clarified the recent spike in its share price and trading volume, attributing the market activity to its acquisition of the Firenze silver and gold project and a successful capital raise.

Scorpion Minerals has addressed recent spikes in its share price and trading volume, attributing the activity to rising global gold prices and imminent assay results from its Pharos Gold Project.

Platina Resources Limited has addressed ASX concerns over a sharp rise in its share price and trading volume, confirming no undisclosed information is driving the activity. The company points to recent project acquisition and heritage clearance announcements as possible catalysts.

Nelson Resources has confirmed it is in confidential negotiations for a Right to Mine contract, explaining recent unusual trading activity in its shares. The company maintains compliance with ASX disclosure rules while awaiting contract finalisation.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Strike Resources (ASX – SRK) has addressed a sharp 50% rise in its share price and trading volume, attributing the activity to developments in Lithium Energy Limited, where it holds a major stake, while denying any undisclosed price-sensitive information.